Compare Modine Manufacturing Company (MOD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Sanofi SA — how do they compare? Modine Manufacturing Company trades at $186.69 (market cap $10.22B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 10.2× Modine Manufacturing Company's market cap, and Sanofi SA pays a 5.61% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| MOD | SNY | |
|---|---|---|
Market Cap | $10.22B | $104.06B |
Sector | Technology | Health |
52-Week High | $306.89 | $52.34 |
52-Week Low | $119.68 | $41.33 |
Enterprise Value | $10.65B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $192.35, down 1.19% on the day, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth driven by data center cooling demand, with Q2 2026 EPS beating estimates at $1.53 versus $1.30 expected. However, valuation metrics appear stretched with a P/E of 71.77 and EV/EBITDA of 35.15, while profit margins face pressure from supply chain constraints.
The outlook remains positive due to strong data center backlog growth and analyst consensus price target of $305, representing 59% upside potential. Key risks include execution challenges in scaling production and margin compression. With 77% of analysts rating MOD as Buy and no Sell ratings, Wall Street maintains bullish sentiment despite near-term volatility.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
